Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other co-defendants, ...

If there's one thing "Abbott Elementary" viewers know about main character Janine Teagues, it's that she'll do anything to ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

The stock's fall snapped a two-day winning streak.

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

The cast of 'Abbott Elementary' are being rewarded for the show's success with major salary increases heading into Season 4.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...